As expected, VRCZ treatment induced translocation of AhR to nucleus and upregulate AhR target genes, CYP1A1, CYP1A2 and CYP1B1 in KCs, indicating that VRCZ serves as AhR activator. The gene discussed is AHR; the disease is dry eye syndrome.